Table 1

Patient demographics and disease characteristics at baseline

CharacteristicsAll patients (n=63 unless specified)
Female, n (%)37 (58.7)
Age (years), mean±SD43.4±15.7
Time since UC diagnosis (days), median (range)*126 (–7 to 784)
Duration of symptoms prior to UC diagnosis, n (%)
 <1 year48 (76.2)
 1–3 years8 (12.7)
 >3 years7 (11.1)
Receiving UC treatment at baseline, n (%)59 (93.7)
Types of UC treatment received at baseline (physician reported), n (%)(n=64)†
 5-aminosalicylic acid or mesalamine42 (65.6)
 Oral systemic steroids10 (15.6)
 Azathioprine or mercaptopurine4 (6.3)
 Aminosalicylates2 (3.1)
 Alternative tumour necrosis factor inhibitors:
  Infusion1 (1.6)
  Biosimilar1 (1.6)
 Sulfasalazine1 (1.6)
 Other (non-listed therapy)3 (4.7)
Employment status, n (%)
 Employed/self-employed44 (69.8)
 Retired11 (17.5)
 On sick leave9 (14.3)
  Related to UC6/9 (66.7)
  Unrelated to UC3/9 (33.7)
 Unemployed4 (6.3)
  Related to UC4/4 (100.0)
  Unrelated to UC0 (0.0)
 Homemaker3 (4.8)
 Student1 (1.6)
Duration of sick leave related to UC(n=6)
 <2 months5 (83.3)
 ≥2 to ≤4 months0 (0.0)
 >4 months1 (16.7)
Duration of unemployment related to UC(n=4)
 <6 months3 (75.0)
 ≥6 to ≤12 months1 (25.0)
≥1 UC-related hospital admissions, n (%)‡13 (20.6)
≥1 UC-related hospital admissions for surgery, n (%)‡4 (6.3)
≥1 associated comorbid diseases/symptoms§, n (%)31 (49.2)
≥1 associated immune mediated diseases, n (%)¶13 (20.6)
  • *All patients had a confirmed UC diagnosis at baseline—time since UC diagnosis was calculated as the difference between date of UC diagnosis and baseline visit date, and the 15th day was used as the default diagnosis date; therefore, negative values can occur.

  • †Not mutually exclusive.

  • ‡During the 6 months prior to the baseline visit.

  • §Relevant comorbid conditions included anxiety/depression, cardiovascular disease, chronic renal deficiency, chronic pulmonary disease, cognitive dysfunction, diabetes mellitus, fatigue, low body weight, polyneuropathy/neuropathy, postural hypertension, skin disease and sleep disorders.

  • ¶Relevant immune-mediated diseases included ankylosing spondylitis, erythema nodosum, hidradenitis suppurativa, primary sclerosing cholangitis, psoriasis, psoriatic arthritis, pyoderma gangrenosum, rheumatoid arthritis and uveitis.

  • UC, ulcerative colitis.